# Verdict: adult_t_cell_leukemia_lymphoma.md (re-verification after fix)

## 1. DOSE LEAK
None. Numeric tokens present in the file: "CD4"/"HTLV-1" (disease/virus names), "3-year" OS,
"~50%" ORR, "~5 months" PFS, "under half" (paraphrase of 42% ORR), "four" subtypes, and
"12th ed." (book edition). No mg, mg/m2, AUC, Gy, or numbered cycle/day/interval schedule
anywhere (the earlier "CHOP-14" numeral is gone, replaced by "dose-dense CHOP-based comparator").

## 2. UNGROUNDED / MISLABELLED CLAIMS
None remaining. Checked against DeVita Ch. 67 "Adult T-cell Leukemia/Lymphoma" section
(devita.txt ~lines 269303-269620):
- Subtype-first framework and the 116-patient retrospective (antiviral benefit in
  acute/chronic/smoldering vs. chemo benefit in lymphomatous) — matches.
- Phase III intensive-regimen-vs-CHOP-comparator trial (higher CRR, no ORR difference, better
  3-yr OS, still poor overall) — matches (source: 24% vs 13% OS), regimen/drug names and doses
  correctly omitted.
- Mogamulizumab ORR ~50%/PFS ~5 mo (phase II, 28 pts), and pre-alloSCT mogamulizumab -> severe
  GVHD risk via Treg depletion — matches.
- Lenalidomide (42% ORR paraphrased as "under half," short PFS) and alemtuzumab (small phase II,
  near-universal CMV antigenemia, short PFS) — match DeVita's figures/framing.
- AlloSCT limited success given poor chemo results alone — matches. The "only potentially
  curative" superlative is now correctly tagged as general-oncology-standard (not DeVita) at
  **both** occurrences: line 20 (already tagged in the prior round) and line 34 ("When to refer,"
  the item this round's fix targeted) — confirmed fixed, no longer reads as DeVita-sourced.
- Hypercalcemia mechanism (PTHrP/TGF-beta/RANKL) and opportunistic-infection list
  (pneumocystis/cryptococcal meningitis/strongyloides/disseminated zoster) — verbatim match,
  correctly attributed to DeVita's clinical-presentation description.
- Surgery/RT section: DeVita's ATLL section has no defined role for these; the "occasional local
  RT" comment is properly tagged as general-standard, not DeVita.
No new fabrication, no remaining untagged superlatives, no other mis-attribution to DeVita found.

## 3. CITATION
Present at line 40: "Sources: DeVita, Hellman, and Rosenberg's Cancer: Principles & Practice of
Oncology, 12th ed." Name + edition only, no page numbers. Compliant.

## 4. VERDICT: CLEAN (ready for R1 re-review)
The single item flagged by the prior verdict (untagged transplant superlative at line 34) is
confirmed fixed by relabelling to match the identical, already-correct tag at line 20. Dose-free
compliance, grounding, and citation format all hold up under this re-check.
